Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients-An Open-Label Phase II Clinical Trial.

Rada M Grubovic RastvorcevaSedula UseiniMilena StevanovicIlir DemiriElena PetkovicMassimo Franchini Daniele Focosi

Published in: Life (Basel, Switzerland) (2022)

This study showed that early administration of CCP to patients with moderate disease was a safe and potentially effective treatment for hospitalized COVID-19 patients. The trial was registered at clinicaltrials.gov (NCT04397523).

Keyphrases

phase ii
clinical trial
open label
sars cov
phase iii
coronavirus disease
double blind
study protocol
placebo controlled
respiratory syndrome coronavirus
combination therapy